Research
Additional Resources
National Clinical Trials
BrainBLOCK STUDYNCCTG 94-72-52 Diagnostic and Prognostic Markers in Anaplastic Astrocytoma and Anaplastic .1credit RX Oligoastrocytoma -BLOCK STUDY LOW GRADE None at this time UNTREATED NCCTG R0525 Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma http://www.cancer.gov/search/ViewClinicalTrials.aspx?drid=465183&version=patient&protocolsearchid=3422358 RECURRENT NCCTG N0272 Phase II trial of STI-571 in treatment of recurrent Oligodendroglioma and mixed Oligoastrocytoma (Temporarily Suspended - Study 1, Arm C (EIAC’s patients) - 2/1/08) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427319 NCCTG N047B Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Recurrent Glioblastoma (Group 1 Permanently Closed - 10/27/06, Group 2 Permanently Closed - 1/3/08) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427322 NCCTG N0572 Phase I/II Trial of Sorafenib and CCI-779 in Patients with Recurrent Glioblastoma (Temporarily Suspended - 03/16/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427324 METASTATIC NCCTG N0574 Phase III Randomized Trial of the Role of Whole Brain Radiation Therapy in Addition to Radiosurgery in the Management of Patients with One to Three Cerebral Metastases http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427332 BR> BreastRADIATION PROTOCOLSNSABP B-39 Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) vs. Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer [Low-Risk Patient Populations Closed to Accrual - 12/30/06 (Women ?50 yrs. with DCIS, regardless of HR status & Women ?50 yrs. w/invasive breast cancer that is node-negative and hormone-receptor positive.] http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427336 DCIS None at this time NEO-ADJUVANT
None at this time CHEMOTHERAPY NSABP B-40 Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=515432&protocolsearchid=3427341&version=patient
NSABP B-36 Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-FU, Epirubicin, and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-Negative Breast Cancer (QOL Closed to Accrual 8/11/06) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427342 ECOG PACCT-1 Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427344 NODE (+) or HIGH RISK NODE (-)
IBCSG 24-02 Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427355 IBCSG 25-02 Phase III Trial Evaluating the Role of Exemestane plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer (Suspended to Accrual - 11/30/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427358 HORMONAL NCCTG MA.17R Double Blind Randomization to Letrozole or Placebo For Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427871 NSABP B-42 Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=502263&protocolsearchid=3427371&version=patient CHEMOTHERAPY CTSU C40101 Cyclophosphamide and Doxorubicin (CA) (4 vs 6 Cycles) vs. Paclitaxel (4 vs 6 Cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A 2x2 Factorial Phase III Randomized Study http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=69444&version=patient&protocolsearchid=3422145 CTSU S0221 Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=334899&version=HealthProfessional&protocolsearchid=3427349 CHEMOTHERAPY - HER2 NEU(+) MCCRC RC0639 Phase II Study of Cardiac Safety and Tolerability of an Adjuvant Chemotherapy plus Trastuzumab with Lapatinib in Patients with Resected HER2+ Breast Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=533793&version=HealthProfessional&protocolsearchid=3879231 NICHE CTSU S0307 Phase III Study of Bisphosphonates as Adjuvant Therapy in Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427352 ECOG S0230 Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Standard Adjuvant Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427860 ADVANCED / METASTATIC
CTSU C40302 Endocrine Therapy With or Without Inhibition of EGF and HER2 Growth Factor Receptors: Randomized, Double-Blind, Placebo-Controlled Phase III Trial for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427876 CTSU S0226 Phase III Randomized Trial of Anastrozole vs. Anastrozole and Fulvestrant as First-Line Therapy for Post-Menopausal Women with Metastatic Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427377 CHEMOTHERAPY NCCTG N0537 Phase II Trial of VEGF Trap in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and/or Taxane (Temporarily Closed to Accrual - 11/6/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427389 FOR HER2 NEU(+) NCCTG N0337 Phase II Study of Capecitabine in Combination with Vinorelbine and Trastuzumab for the Second-Line Treatment of HER2+ Metastatic Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427384 ECOG E1105 Randomized Phase III Double-Blind Placebo-Controlled Trial of First-Line Chemotherapy and Trastuzumab with or without Bevacizumab for Patients with HER-2/NEU Over-Expressing Metastatic Breast Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=561762&version=HealthProfessional&protocolsearchid=4357878 Sopherion STm01-102 A Phase III Randomized, Controlled Trial of Myocet, Trastuzumab, and Paclitaxel versus Trastuzumab and Paclitaxel for First Line Therapy of Metastatic Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427385 LOCO REGIONAL NSABP B-37 Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427398 NICHE AnalNone at this timeColonADJUVANT/RESECTED ECOGE5202 Randomized Phase III Study Comparing 5-FU, Leucovorin, & Oxaliplatin vs. 5-FU, Leucovorin, Oxaliplatin & Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427402 CTSU N0147 Randomized Phase III Trial of Irinotecan (CPT-11) and/or Oxaliplatin (OXAL) plus 5-FU/Leucovorin (CF) after Curative Resection for Patients with Stage III Colon Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427399 METASTATIC ECOG E4203 Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427409 CTSU C80405 Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (QOL Closed to Accrual – 8/31/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427414 NSABP C-10 Phase II Trial of 5-Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) Chemotherapy plus Bevacizumab for Patients with Unresectable Stage IV Colon Cancer and a Synchronous Asymptomatic Primary Tumor http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427407 CTSU S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=551934&version=HealthProfessional&protocolsearchid=4184407 LiverNone at this timeRectumNEO-ADJUVANTNSABP R-04 Clinical Trial Comparing Preop Radiation Therapy and Capecitabine w/ Preop Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-FU in the Treatment of Patients w/ Operable Carcinoma of the Rectum http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427424 ECOG E3204 Phase II Study of Preoperative Radiation with Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients with Locally Advanced Rectal Cancer (Suspended to Accrual – 1/9/08) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427428 ADJUVANT ECOG E5204 Intergroup Randomized Phase III Trial of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427426 METASTATIC ECOG E4203 Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427409 CTSU C80405 Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (QOL Closed to Accrual – 8/31/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427413 CTSU S0600 Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab (NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line Therapy for Patients with Metastatic Colorectal Cancer who have Progressed on Bevacizumab with Either FOLFOX, OPTIMOX or XELOX http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=551934&version=HealthProfessional&protocolsearchid=4184407 Esophagus / GE JunctionNEO-ADJUVANTNone at this time ADJUVANT CTSU C80101 Adjuvant chemoradiation after resection of gastric and Gastroesophageal adenocarcinoma http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=258787&protocolsearchid=3422453&version=patient METASTATIC ECOG C80403 Randomized Phase II study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=505535&version=HealthProfessional&protocolsearchid=4106198 SMALL BOWELADVANCED / METASTATICNCCTG N0543 Suspended for Amendment Phase II Trial of Pharmacogenetic-Based Dosing of Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy for Advanced Small Bowel http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=528263&version=HealthProfessional&protocolsearchid=4325232 Stomach / GE JunctionADJUVANTCTSU C80101 Adjuvant chemoradiation after resection of gastric and Gastroesophageal adenocarcinoma http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=258787&protocolsearchid=3422453&version=patient METASTATIC None at this time Gallbladder / Bile DuctNone at this timePancreasLOCALLY ADVANCEDNone at this time METASTATIC None at this time ADJUVANT None at this time NEOADJUVANT None at this time GUBladderADJUVANTNone at this time RenalRENAL ADJUVANTECOG E2805 Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib vs Sorafenib vs Placebo in Patients with Resected Renal Cell Carcinoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427450 METASTATIC None at this time COLLECTING DUCT None at this time UrotheliumADVANCEDNone at this time ProstateADJUVANTNone at this time ADVANCED / METASTATIC ECOG S9346 Intermittent Androgen Deprivation in Patients with Stage D2 Prostate Cancer (ECOG does not participate in the ancillary study SWOG 9405) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427461 ECOG E3805 CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427486 CTSU S0421 Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427479 ECOG E3803 Phase II Study of a Weekly Schedule of BMS-247550 for Patients with Hormone Refractory Prostate Cancer (“No Prior Chemotherapy” Stratum – Closed to Accrual – 10/18/06, “Prior Taxane” Stratum – Closed to Accrual – 1/26/07, and “Two Prior Cytotoxic Chemotherapies” Stratum – Suspended 11/21/06) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427467 ECOG E5805 Phase II Trial of E7389 (Halichondrin B Analog), in Patients with Metastatic Hormone Refractory Prostate Cancer (“Prior Taxane” Stratum – Suspended to Accrual – 7/5/07, “Two Prior Cytotoxic Chemotherapies” Stratum – Suspended to Accrual – 10/10/07, “No Prior Cytotoxic Chemotherapies” Stratum – Suspended to Accrual – 12/11/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427484 NICHE CTSU C90202 Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early vs. Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3428061 Germ CellNone at this timePenileNone at this timeGYNGOG 130EEvaluation of Docetaxel and Gemcitabine in Recurrent or Persistent Carcinosarcoma of the Uterus (130 series) (Temporarily Closed to Accrual – 10/29/07) GOG 136 Acquisition of Human Gynecologic Specimens and Serum to be Used in Studying the Causes, Diagnosis, Prevention and Treatment of Cancer GOG 146Q Phase II Evaluation of Topotecan (NSC #609699) Administered Daily X 5 Every 3 Weeks vs. Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=434848&version=HealthProfessional&protocolsearchid=3879818 GOG 173 Intraoperative Lymphatic Mapping and Sentinel Node (SN) Identification in Patients with Squamous Carcinoma of the Vulva http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=66277&version=HealthProfessional&protocolsearchid=3879818 GOG 209 Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs. Carboplatin/Paclitaxel in Patients with Stage III & IV or Recurrent Endometrial Cancer (Suspended to Accrual for patients who have received any prior external radiation therapy – 11/1307) http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=305940&version=HealthProfessional&protocolsearchid=3879818 GOG 215 Phase II Randomized Study of the Effect of Zoledronic Acid versus Observation on Bone Mineral Density of the Lumbar Spine in Women who Elect to Undergo Surgery that Results in Removal of Both Ovaries http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=462217&version=HealthProfessional&protocolsearchid=3879818 GOG 218 Phase III Trial of Carboplatin and Paclitaxel plus Placebo versus Carboplatin and Paclitaxel plus Concurrent Bevacizumab (NSC #704865, IND #7921) followed by Placebo, versus Carboplatin and Paclitaxel plus Concurrent and Extended Bevacizumab in Women with Newly Diagnosed, Previously Untreated, Suboptimal Advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=455114&version=HealthProfessional&protocolsearchid=3879818 OCEANS Phase II, Multicenter, Randomized Blinded, Placebo-Controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients with Platinum-Sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=537828&version=HealthProfessional&protocolsearchid=3879846 TEACO A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel with Bevacizumab as First Line Therapy in Patients with FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma. CervicalNone at this time (see Cancer Control)UterusNone at this timeHead & NeckNEO-ADJUVANTNone at this time ADVANCED / RECURRENT ECOG E1302 Phase III Randomized, Placebo-Controlled, Trial of Docetaxel vs. Docetaxel plus ZD1839 (Iressa, Gefitinib) in Performance Status 2 or Previously Treated Patients with Recurrent or Metastatic Head and Neck Cancer (Permanently Closed to Accrual – Step 2, Arm C – 8/23/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427487 ECOG E1304 Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (VELCADE) in Combination with Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients with Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) (Suspended to Accrual – Arm A ONLY – 1/2/08) http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=409577&protocolsearchid=3427489&version=patient ThymomaADVANCEDNone at this time LymphomasNON-HODGKIN’S LYMPHOMAS
ECOG E4402 – (Follicular Grade 1 & 2) (Small Lymphocytic) [Marginal Zone (Nodal or Splenic)] (MALT) Randomized Phase III Trial Comparing Two Different Rituximab Dosing Regimens for Patients with Low Tumor Burden Indolent non-Hodgkin’s Lymphoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427498 INTERMEDIATE GRADE None at this time HIGH GRADE CTSU C50303 – (DLCL) Phase III Randomized Study of R-CHOP v. Dose-adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas (Suspended to Accrual – 1/31/08) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427981 ECOG E3404 – (DLCL) Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427513 ECOG E2404 – (Immunosuppressive Disorders) Bevacizumab and CHOP (A-CHOP) in Combination for Patients with Peripheral T-Cell or Natural Killer Cell Neoplasms http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=441194&protocolsearchid=3427532&version=patient 2nd LINE TREATMENT
None at this time INTERMEDIATE GRADE None at this time HIGH GRADE MCCRC MC0485 – (DLCL, Mantle Cell, or Low Grade ? DLCL) Phase II Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone with Rituxan (ROAD) in Patients with Relapse CD20+ B-Cell Non-Hodgkin’s Lymphoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=2569710 MANTLE CELL ECOG E1405 – (1st Line) Phase II Study of VcR-CVAD with Rituximab Maintenance for Untreated Mantle Cell Lymphoma http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=528926&protocolsearchid=3499477&version=patient NCCTG N038H – (Relapsed or Refractory) Phase II Study of CCI-779 in Combination with Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427527 PRIMARY CNS ECOG E1F05 Phase II Study of Rituximab Given in Conjunction with Standard Chemotherapy in Primary Central Nervous System (CNS) Lymphoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427530 HODGKIN’S LYMPHOMAS None at this time Immunosuppressive DisordersNone at this timeMyelodyplastic SyndromeECOG E1905Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia (Suspended to Accrual – 9/5/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427534 LeukemiasALLECOG E1904 Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) with Subcutaneous Campath for Adults with Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427536 AML ECOG E1900 Phase III trial in adult AML: Daunorubicin dose intensification and gemtuzumab ozogamicin consolidation therapy prior to autologous stem cell transplantation (Suspended to Accrual – 2/16/08) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427990 ECOG E2902 Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission after Primary Induction Failure (Suspended to Accrual – 8/8/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427544 CTSU S0106 Phase III Study of the Addition of Gemtuzumab Ozogamicin Induction Therapy vs. Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin or No Additional Therapy for Patients Under Age 56 with Previously Untreated De Novo Acute Myeloid Leukemia (AML) – (Use Ancillary Study S9910 with this study) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427545 ECOG E1905 Randomized Phase II Trial of Azacitidine with or without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (dysplastic type), and Acute Myeloid Leukemia with Multilineage Dysplasia (Suspended to Accrual – 9/5/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427533 APL None at this time CLL ECOG E2903 Phase II Trial of Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath-1H for Previously Treated Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia (CLL) http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=343796&version=HealthProfessional&protocolsearchid=3685971 LGL ECOG E5998 Phase II study of initial treatment with methotrexate in large granular lymphocytic Leukemia http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3428015 CML ECOG S0325 Phase IIb Study of Molecular Responses to Imatinib at Standard or Increased Doses for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase [Closed to Accrual (ARM 2 ONLY) – 2/1/07] http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427633 AmyloidosisNone at this timeMYELOFIBROSISNone at this timeWaldenstromsNone at this timeLungNON-SMALL CELL
ECOG E1505 Phase III Randomized Trial of Adjuvant Chemotherapy with or without Bevacizumab for Patients with Completely Resected Stage IB (>/= 4 cm) –IIIA Non-Small Cell Lung Cancer (NSCLC) http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=475774&version=HealthProfessional&protocolsearchid=4220630 ADVANCED / NON-RESECTABLE NCCTG N0321 Phase I/II Study of PS-341 in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for NSCLC (Phase 1 Temporarily Closed – 1/29/08) http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=390108&protocolsearchid=3427636&version=patient NCCTG N0528 Randomized Phase II Study of Gemcitabine and Carboplatin with or without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=468945&version=HealthProfessional&protocolsearchid=3719761 CTSU R0617 (N0628) Randomized Phase III Comparison of Standard Dose (60 Gy) Versus High-Dose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel in Patients with Stage IIIA/IIIB NSCLC http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=564240&version=HealthProfessional&protocolsearchid=4325247 BRONCHIOALVEOLAR CARCINOMA ECOG E1504 Phase II Study of C225 (Cetuximab) for the Treatment of Patients with Advanced Bronchioalveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427644 METASTATIC NCCTG N0528 Randomized Phase II Study of Gemcitabine and Carboplatin with or without AZD2171 as First-Line Therapy in Advanced Non-Small Cell Lung Cancer ] http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=468945&version=HealthProfessional&protocolsearchid=3719761 CANCER CONTROL ECOG E5597 Phase III chemoprevention trial of Selenium supplementation in person with resected stage I non-small cell lung cancer http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3428022 PANCOAST None at this time SMALL CELL
None at this time EXTENSIVE ECOG E5501 Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer: Topotecan Sequenced with Etoposide / Cisplatin and Irinotecan / Cisplatin Sequenced with Etoposide http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3428023 MesotheliomaECOG E1B03Pemetrexed Plus Gemcitabine or Carboplatin in Patients with Advanced Malignant Mesothelioma: A Randomized Phase II Trial (Suspended to Accrual – Arms A and B – 7/12/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427667 MelanomaDESMOPLASTICNCCTG N0275 Phase II Trial Evaluating Resection followed by Adjuvant Radiation Therapy (RT) for Patients with Desmoplastic Melanoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427671 ADJUVANT ECOG E1697 Phase III randomized study of four weeks high dose IFN-2b in stage T-3-T-4 or N1 Melanoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427675 UNRESECTABLE / LOCALLY ADVANCED ECOG E2603 Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427680 METASTATIC ECOG E1602 Randomized Phase II Trial of Multi-epitope Vaccination in Melanoma Peptides for Cytotoxic T-Cells and Helper T-Cells for Patients with Metastatic Melanoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427682 ECOG E2602 Phase II Study of Low Dose Peginterferon Alfa-2b in Patients with Metastatic Melanoma Over-Expressing Basic Fibroblast Growth Factor (Suspended to Accrual – 1/17/08) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3428032 ECOG E2603 Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and BAY 43-9006 versus Carboplatin, Paclitaxel and placebo in Patients with Unresectable Locally Advanced or Stage IV Melanoma http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427680 NCCTG N057E Phase II Trial of Carboplatin (CBDCA) and ABI-007 (ABX) in Patients with Unresectable Stage IV Melanoma (Permanently Closed – Cohort II (no prior chemotherapy) ONLY – 6/27/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427685 MyelomaMULTIPLE MYELOMANone at this time SarcomasNEO-ADJUVANTNone at this time ADJUVANT None at this time ADVANCED / METASTATIC None at this time Unknown PrimaryNone at this timeCancer controlANEMIAMCCRC MC04CC Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin alfa for Cancer Patients with Chemotherapy-Associated Anemia (Link not available) ANOREXIA / WEIGHT LOSS None at this time ASCITESNCCTG N04C2 Exploratory, Randomized, Placebo-Controlled Trial of Depot Octreotide (Sandostatin LAR Depot) for Symptomatic Ascites in Cancer Patients http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=440922&version=HealthProfessional&protocolsearchid=3670532 BONE None at this time BRAIN None at this time BREAST ECOG E2Z04 Quality of Life in Younger Breast Cancer Survivors http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=460234&version=HealthProfessional&protocolsearchid=3762476 NCCTG N063I Changes in Breast Density and Plasma Hormone Levels After One Year of Aromatase Inhibitor Therapy http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=560200&version=HealthProfessional&protocolsearchid=4325255 CERVICAL None at this time COLON None at this time DIARRHEA None at this time FATIGUE None at this time HAND AND FOOT SYNDROME NCCTG N05C5 Phase III Randomized, Placebo-Controlled, Double-blind Trial to Determine the Effectiveness of a Urea/Lactic Acid-Based Topical Keratolytic Agent and Vitamin B-6 for Prevention of Capecitabine-Induced Hand and Foot Syndrome (Closed to Accrual (full board approval of Addendum 5 required before accrual permitted) – 11/23/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427717 HOT FLASHES None at this time LIBIDO None at this time LUNG CTSU S0424 Molecular Epidemiology Case-Series Study of Non-Small Cell Lung Cancer in Smoking and Non-Smoking Women and Men (Temporarily Closed – Female and Male Smoking Strata ONLY – 7/15/07) http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427721 LYMPHOMA None at this time MULTIPLE MYELOMA None at this time MYELODSPLASTIC SYND. None at this time NAUSEA / VOMITTING None at this time NEUROPATHY None at this time OTHERS None at this time PAIN None at this time PROSTATE None at this time RECTUM None at this time SKIN / RASH NCCTG N03CB An Exploratory, Placebo-Controlled Trial of Prophylactic Tetracycline for Gefitinib- or Cetuximab-Induced Skin Rash (or Other Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Skin Rash) (Closed to Accrual – 2/22/08) http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=385682&version=HealthProfessional&protocolsearchid=3979961 SLEEP None at this time SMOKING None at this time VAGINAL DRYNESS NCCTG N04CA Pilocarpine For Vaginal Dryness: Phase III Randomized, Double-blind, Placebo-Controlled Study http://www.cancer.gov/search/ResultsClinicalTrialsAdvanced.aspx?protocolsearchid=3427733
CP-BREAST |
